Business Description
Surgical Science Sweden AB
ISIN : SE0014428512
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 15.85 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.15 | |||||
Interest Coverage | 36.54 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 13.67 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 78.5 | |||||
3-Year EBITDA Growth Rate | 80.6 | |||||
3-Year EPS without NRI Growth Rate | 116.9 | |||||
3-Year FCF Growth Rate | 108.1 | |||||
3-Year Book Growth Rate | 90.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 17.51 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.83 | |||||
9-Day RSI | 47.14 | |||||
14-Day RSI | 46.99 | |||||
6-1 Month Momentum % | 17.9 | |||||
12-1 Month Momentum % | -18.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.22 | |||||
Quick Ratio | 3.56 | |||||
Cash Ratio | 2.7 | |||||
Days Inventory | 211.5 | |||||
Days Sales Outstanding | 57.98 | |||||
Days Payable | 72.32 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.9 | |||||
Shareholder Yield % | -0.58 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 69.42 | |||||
Operating Margin % | 21.43 | |||||
Net Margin % | 26.5 | |||||
FCF Margin % | 21.92 | |||||
ROE % | 5.36 | |||||
ROA % | 4.9 | |||||
ROIC % | 3.93 | |||||
ROC (Joel Greenblatt) % | 406.35 | |||||
ROCE % | 6.01 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 32.94 | |||||
Forward PE Ratio | 31.25 | |||||
PE Ratio without NRI | 32.94 | |||||
Price-to-Owner-Earnings | 37.27 | |||||
PEG Ratio | 0.38 | |||||
PS Ratio | 8.73 | |||||
PB Ratio | 1.78 | |||||
Price-to-Tangible-Book | 9.98 | |||||
Price-to-Free-Cash-Flow | 39.67 | |||||
Price-to-Operating-Cash-Flow | 32.34 | |||||
EV-to-EBIT | 26.55 | |||||
EV-to-Forward-EBIT | 24.91 | |||||
EV-to-EBITDA | 26.55 | |||||
EV-to-Forward-EBITDA | 20.72 | |||||
EV-to-Revenue | 8.09 | |||||
EV-to-Forward-Revenue | 6.92 | |||||
EV-to-FCF | 36.67 | |||||
Price-to-Projected-FCF | 1.69 | |||||
Price-to-Graham-Number | 3.72 | |||||
Price-to-Net-Current-Asset-Value | 11.53 | |||||
Price-to-Net-Cash | 26.19 | |||||
Earnings Yield (Greenblatt) % | 3.77 | |||||
FCF Yield % | 2.51 |